Kawale, Ajinkya S., and Lee Zou. “ Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer. ” DNA Repair (Amst) 141 (September 2024): 103734. https://doi.org/10.1016/j.dnarep.2024.103734.

Currently, our research is focused on three fundamental questions about checkpoint signaling. First, how is checkpoint activated by DNA damage in cells? Second, how does checkpoint transmit DNA damage signals through different types of protein modifications? Third, how does checkpoint protect the DNA replication forks encountering DNA damage?

The Zou laboratory is particularly interested in understanding how the checkpoint detects DNA damage and genomic instability, and how the checkpoint can be targeted in cancer therapy. Our current studies are focused on understanding the molecular mechanisms by which different types of oncogenic events give rise to replication stress and genomic ...

2022年10月3日 · Lee Zou, PhD, has been named the new chair of the Department of Pharmacology and Cancer Biology. He will begin his new role on Feb. 1, 2023. Colin Duckett, PhD, Vice Dean for Basic Science and Professor of Pharmacology and Cancer Biology, has served as interim chair of the department since September 2020.

Lee Zou. Duke University. Verified email at duke.edu. Articles Cited by Public access. Title. Sort. Sort by citations Sort by year Sort by title. Cited by. Cited by. Year; Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. L Zou, SJ …

2018-2028 American Society for Pharmacology and Experimental Therapeutics. 2023-2026 Massachusetts General Hospital. 2023-2025 Lung Cancer Research Foundation.

The laboratory of MGH Research Scholar Lee Zou, PhD, is investigating the genetic and epigenetic changes in the human genome that contribute to the development of cancer. Cancer is a complex disease driven by genetic and epigenetic alterations in the genome.

[email protected] George Barth Geller Distinguished Professor Professor of Pharmacology and Cancer Biology Chair, Department of Pharmacology and Cancer Biology Member of the Duke Cancer Institute

2024年3月19日 · Journal Article Clin Cancer Res · January 6, 2025 PURPOSE: Preclinical studies have identified molecular correlates of sensitivity to ATR inhibition. This translational study was designed to test the ATR inhibitor berzosertib in patients with advanced solid tumors carrying alterations in ATRX, ataxia-tela ... Full text Link to item Cite.

2023年12月5日 · Lee Zou, PhD, joined the Duke faculty in March 2023 as chair of the Department of Pharmacology and Cancer Biology in part because of the very collegial environment he found in Durham. He was previously professor of pathology at Harvard Medical School and scientific co-director of Massachusetts General Cancer Center.